Millen et al. demonstrated that a high level of CD8+ tumor immune infiltrating cells and a clinical history of longer relapse-free survival were related to high expression of MYB. An immunomodulatory effect conferred by MYB was also observed in CD8+ TILs in the murine CRC model [40]. This evidence concerns the gene CD8A and neoplasm.